LIVINGSTON, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. , which develops, manufactures and markets computer controlled local anesthetic delivery systems, today announced that a large scale independent clinical study on children demonstrated that the CompuDent(R) system and its disposable Wand(R) handpiece represent a superior alterative for administering local anesthetic injections to pediatric patients (ages 2 to 13 years), when compared with traditional techniques performed with a conventional syringe. The study is a featured article in the October issue of the Journal of the American Dental Association (“JADA”), the prestigious official publication of the American Dental Association.
The independent study evaluated results from the examination of 193 children ages 2 to 13 years who received dental treatment in two separate pediatric dental clinics in Israel. The study evaluated anesthesia effectiveness, patient pain reactions, behavior cooperation and post-treatment dental pain, among other factors. The authors reported a success rate using the CompuDent(R) system of over 95% for routine dental fillings, and a mean effectiveness of 90% (upper primary molar teeth) and 89% (lower primary molar teeth) for all dental treatments performed. The doctors performing the study are members of the faculty of the Department of Pediatric Dentistry at the Maurice and Gabriela Goldschleger School of Dental Medicine, Tel-Aviv University, Israel.
“This study provides new evidence for the effectiveness of our technology for the care of younger patients,” stated Mark Hochman, Director of Clinical Affairs at Milestone Scientific Inc. “The study allows us to demonstrate to the global dental profession the importance of integrating our technology into treatment modalities for children, as well as all other dental patients,” added Leonard Osser, Chief Executive Officer of the Company.
About Milestone Scientific Inc.
Milestone Scientific is the developer, manufacturer and marketer of CompuMed(R) and CompuDent(R) computer controlled local anesthetic delivery systems. These systems comprise a microprocessor controlled drive unit as well as The Wand(R) handpiece, a single patient use product that is held in a pen-like manner for injections. The Company also sells the SafetyWand(R), which incorporates engineered sharps injury protection features to aid in the prevention of accidental needlesticks. Milestone has also developed proprietary consumer (Ionic White) and professional (Cool Blue) teeth whitening systems that were introduced to the market earlier this year.
In 2001, Milestone Scientific received broad United States patent protection on an enabling technology for computer controlled, pressure sensitive infusion, perfusion, suffusion and aspiration, which provides real time displays of pressures, fluid densities and flow rates, that advances the delivery and removal of a wide array of fluids. Development of this CompuFlo technology is currently underway.
The Company is headquartered in Livingston, New Jersey, and its common stock trades on the American Stock Exchange under the symbol “MS”.
This press release contains forward-looking statements regarding the timing and financial impact of the Milestone’s ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report on Form 10-KSB for the year ended December 31, 2004. The forward looking-statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward- looking statements for any reason.
CONTACT Leonard Osser, CEO Stu Wildhorn - President Milestone Scientific Inc. (973) 535-2717; (973) 535-2829 (Fax) Web site: www.milesci.com
Milestone Scientific Inc.
CONTACT: Leonard Osser, CEO, or Stu Wildhorn - President, both ofMilestone Scientific Inc., +1-973-535-2717, or fax, +1-973-535-2829
Web site: http://www.milesci.com//
